This study is looking at how tiny bits of cancer DNA, called circulating tumor DNA (ctDNA), found in your blood can help doctors understand breast cancer. After you've had your main treatment, even a few remaining cancer cells (minimal residual disease or MRD) can cause cancer to return. By tracking ctDNA through simple blood tests, researchers hope to learn if this can predict if your cancer will come back or if your treatment is working. This is an observational study, meaning there are no new treatments given. It aims to enroll 900 people with different types of breast cancer, including triple-negative (TNBC), HR positive/HER2 negative, and HER2 positive breast cancer. The goal is to improve how doctors manage breast cancer in the future.

Study design

This is an observational study, meaning no new treatments are given. It plans to include 900 participants aged 18 to 99 years old who have been diagnosed with breast cancer.

What's involved

You would need to be willing to participate in the research and provide blood samples. The study does not specify the number of visits or procedures.

Compensation

Not stated in the trial record.

Follow-up

The study will track your Invasive Disease-Free Survival (how long you live without the cancer returning or getting worse) for up to 5 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.